163 related articles for article (PubMed ID: 34503204)
21. Clinical relevance of the combined analysis of circulating tumor cells and anti-tumor T-cell immunity in metastatic breast cancer patients.
Muraro E; Del Ben F; Turetta M; Cesselli D; Bulfoni M; Zamarchi R; Rossi E; Spazzapan S; Dolcetti R; Steffan A; Brisotto G
Front Oncol; 2022; 12():983887. PubMed ID: 36081561
[TBL] [Abstract][Full Text] [Related]
22. Acquired
Nesic K; Kondrashova O; Hurley RM; McGehee CD; Vandenberg CJ; Ho GY; Lieschke E; Dall G; Bound N; Shield-Artin K; Radke M; Musafer A; Chai ZQ; Ghamsari MRE; Harrell MI; Kee D; Olesen I; McNally O; Traficante N; Australian Ovarian Cancer Study ; DeFazio A; Bowtell DDL; Swisher EM; Weroha SJ; Nones K; Waddell N; Kaufmann SH; Dobrovic A; Wakefield MJ; Scott CL
Cancer Res; 2021 Sep; 81(18):4709-4722. PubMed ID: 34321239
[TBL] [Abstract][Full Text] [Related]
23. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK
J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830
[TBL] [Abstract][Full Text] [Related]
24. Homologous Recombination Deficiency Score Determined by Genomic Instability in a Romanian Cohort.
Rădoi VE; Țurcan M; Maioru OV; Dan A; Bohîlțea LC; Dumitrescu EA; Gheorghe AS; Stănculeanu DL; Thodi G; Loukas YL; Săbău ID
Diagnostics (Basel); 2023 May; 13(11):. PubMed ID: 37296748
[TBL] [Abstract][Full Text] [Related]
25. Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer.
Sztupinszki Z; Diossy M; Borcsok J; Prosz A; Cornelius N; Kjeldsen MK; Mirza MR; Szallasi Z
Clin Cancer Res; 2021 Oct; 27(20):5681-5687. PubMed ID: 34380641
[TBL] [Abstract][Full Text] [Related]
26. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
[TBL] [Abstract][Full Text] [Related]
27. Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders.
Yang C; Zhang Z; Tang X; Zhang X; Chen Y; Hu T; Zhang H; Guan M; Zhang X; Wu Z
Hum Cell; 2022 Jan; 35(1):199-213. PubMed ID: 34628623
[TBL] [Abstract][Full Text] [Related]
28. A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer Diagnosis.
Guarischi-Sousa R; Kroll JE; Bonaldi A; Pierry PM; Villela D; Souza CA; Silva JS; Bürger MC; Oliveira FA; de Paula MG; Meliso FM; de Almeida LG; Monfredini PM; de Oliveira AG; Milanezi F; Scapulatempo-Neto C; Yamamoto GL
Diagnostics (Basel); 2023 Oct; 13(21):. PubMed ID: 37958189
[TBL] [Abstract][Full Text] [Related]
29. A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.
Dong F; Davineni PK; Howitt BE; Beck AH
Cancer Epidemiol Biomarkers Prev; 2016 Nov; 25(11):1511-1516. PubMed ID: 27496093
[TBL] [Abstract][Full Text] [Related]
30. Homologous Recombination Deficiency and Ovarian Cancer Treatment Decisions: Practical Implications for Pathologists for Tumor Typing and Reporting.
Rabban JT; Chen LM; Devine WP
Surg Pathol Clin; 2022 Jun; 15(2):219-234. PubMed ID: 35715159
[TBL] [Abstract][Full Text] [Related]
31. Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
Filippova OT; Selenica P; Pareja F; Vahdatinia M; Zhu Y; Pei X; Riaz N; Long Roche K; Chi DS; Abu-Rustum NR; Ellenson LH; Reis-Filho JS; Zamarin D; Weigelt B
Gynecol Oncol; 2021 May; 161(2):545-552. PubMed ID: 33674143
[TBL] [Abstract][Full Text] [Related]
32. CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy.
Komdeur FL; Wouters MC; Workel HH; Tijans AM; Terwindt AL; Brunekreeft KL; Plat A; Klip HG; Eggink FA; Leffers N; Helfrich W; Samplonius DF; Bremer E; Wisman GB; Daemen T; Duiker EW; Hollema H; Nijman HW; de Bruyn M
Oncotarget; 2016 Nov; 7(46):75130-75144. PubMed ID: 27650547
[TBL] [Abstract][Full Text] [Related]
33. Characteristics of T-Cell Receptor Repertoire and Correlation With
Yang H; Wang Y; Jia Z; Wang Y; Yang X; Wu P; Song Y; Xu H; Gu D; Chen R; Xia X; Bing Z; Gao C; Cao L; Li S; Cao Z; Liang N
Front Oncol; 2021; 11():537735. PubMed ID: 33777727
[TBL] [Abstract][Full Text] [Related]
34. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
[No Abstract] [Full Text] [Related]
35. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
36. PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
Chen H; Molberg K; Strickland AL; Castrillon DH; Carrick K; Jiang Q; Niu S; Rivera-Colon G; Gwin K; Hinson S; Lea J; Miller DS; Zheng W; Lucas E
Am J Surg Pathol; 2020 Aug; 44(8):1050-1060. PubMed ID: 32384321
[TBL] [Abstract][Full Text] [Related]
37. Unraveling the Transcriptomic Signatures of Homologous Recombination Deficiency in Ovarian Cancers.
Lee JJ; Kang HJ; Kim SS; Charton C; Kim J; Lee JK
Adv Biol (Weinh); 2022 Dec; 6(12):e2200060. PubMed ID: 36116121
[TBL] [Abstract][Full Text] [Related]
38. Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors.
Miller RE; Elyashiv O; El-Shakankery KH; Ledermann JA
Onco Targets Ther; 2022; 15():1105-1117. PubMed ID: 36217436
[TBL] [Abstract][Full Text] [Related]
39. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
Ashley CW; Da Cruz Paula A; Kumar R; Mandelker D; Pei X; Riaz N; Reis-Filho JS; Weigelt B
Gynecol Oncol; 2019 Jan; 152(1):11-19. PubMed ID: 30415991
[TBL] [Abstract][Full Text] [Related]
40. TCR Coexpression Signature Predicts Immunotherapy Resistance in NSCLC.
Wang Y; Liu Y; Li X; Li W; Xue Z; He X; Xiong W; He L; Bai Y
Front Pharmacol; 2022; 13():875149. PubMed ID: 35600862
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
